Chace D[au] - Search Results

Year	Number of Results
1986	2
1989	1
1990	2
1991	1
1992	1
1993	7
1994	5
1995	4
1996	1
1997	4
1998	1
1999	3
2000	2
2001	5
2002	2
2003	6
2004	3
2005	7
2006	4
2007	2
2008	5
2009	5
2010	6
2011	3
2012	4
2013	1
2014	3
2015	1
2016	1
2017	1
2020	2
2022	0

1

Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD. Doronina SO, et al. Among authors: chace df. Nat Biotechnol. 2003 Jul;21(7):778-84. doi: 10.1038/nbt832. Epub 2003 Jun 1. Nat Biotechnol. 2003. PMID: 12778055

2

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF. Francisco JA, et al. Among authors: chace df. Blood. 2003 Aug 15;102(4):1458-65. doi: 10.1182/blood-2003-01-0039. Epub 2003 Apr 24. Blood. 2003. PMID: 12714494 Free article.

3

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.

Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA. Hamblett KJ, et al. Among authors: chace df. Clin Cancer Res. 2004 Oct 15;10(20):7063-70. doi: 10.1158/1078-0432.CCR-04-0789. Clin Cancer Res. 2004. PMID: 15501986

4

Microsample analyses via DBS: challenges and opportunities.

Henion J, Oliveira RV, Chace DH. Henion J, et al. Among authors: chace dh. Bioanalysis. 2013 Oct;5(20):2547-65. doi: 10.4155/bio.13.197. Bioanalysis. 2013. PMID: 24138627 Review.

5

Progressive Metabolic Dysfunction and Nutritional Variability Precedes Necrotizing Enterocolitis.

Sinclair TJ, Ye C, Chen Y, Zhang D, Li T, Ling XB, Cohen HJ, Shaw GM, Stevenson DK, Chace D, Clark RH, Sylvester KG. Sinclair TJ, et al. Among authors: chace d. Nutrients. 2020 Apr 30;12(5):1275. doi: 10.3390/nu12051275. Nutrients. 2020. PMID: 32365850 Free PMC article.

6

Mass spectrometry in the clinical laboratory.

Chace DH. Chace DH. Chem Rev. 2001 Feb;101(2):445-77. doi: 10.1021/cr990077+. Chem Rev. 2001. PMID: 11712254 Review. No abstract available.

7

Proteomics- and metabolomics-based neonatal diagnostics in assessing and managing the critically ill neonate.

Spitzer AR, Chace D. Spitzer AR, et al. Among authors: chace d. Clin Perinatol. 2008 Dec;35(4):695-716, vi. doi: 10.1016/j.clp.2008.07.019. Clin Perinatol. 2008. PMID: 19026335 Review.

8

Altered metabolism and newborn screening using tandem mass spectrometry: lessons learned from the bench to bedside.

Chace DH, Spitzer AR. Chace DH, et al. Curr Pharm Biotechnol. 2011 Jul;12(7):965-75. doi: 10.2174/138920111795909104. Curr Pharm Biotechnol. 2011. PMID: 21466463 Review.

9

Filter Paper as a Blood Sample Collection Device for Newborn Screening.

Chace DH, Hannon WH. Chace DH, et al. Clin Chem. 2016 Mar;62(3):423-5. doi: 10.1373/clinchem.2015.252007. Epub 2016 Jan 21. Clin Chem. 2016. PMID: 26797689 No abstract available.

10

A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing.

Chace DH, Kalas TA. Chace DH, et al. Clin Biochem. 2005 Apr;38(4):296-309. doi: 10.1016/j.clinbiochem.2005.01.017. Clin Biochem. 2005. PMID: 15766731 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results